JP2013509388A - マラリアの治療または予防におけるフェロキンの使用 - Google Patents
マラリアの治療または予防におけるフェロキンの使用 Download PDFInfo
- Publication number
- JP2013509388A JP2013509388A JP2012535910A JP2012535910A JP2013509388A JP 2013509388 A JP2013509388 A JP 2013509388A JP 2012535910 A JP2012535910 A JP 2012535910A JP 2012535910 A JP2012535910 A JP 2012535910A JP 2013509388 A JP2013509388 A JP 2013509388A
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- treatment
- vivax
- infection
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000011282 treatment Methods 0.000 title claims description 20
- 230000002265 prevention Effects 0.000 title claims description 13
- 201000004792 malaria Diseases 0.000 title description 14
- 241000223810 Plasmodium vivax Species 0.000 claims abstract description 38
- 244000045947 parasite Species 0.000 claims abstract description 29
- 208000015181 infectious disease Diseases 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 241000223821 Plasmodium malariae Species 0.000 claims abstract description 14
- 206010035501 Plasmodium malariae infection Diseases 0.000 claims abstract description 13
- 210000004185 liver Anatomy 0.000 claims abstract description 12
- 239000002207 metabolite Substances 0.000 claims abstract description 12
- 241000224016 Plasmodium Species 0.000 claims abstract description 10
- 210000003812 trophozoite Anatomy 0.000 claims description 10
- 210000003494 hepatocyte Anatomy 0.000 claims description 8
- 210000000601 blood cell Anatomy 0.000 claims description 6
- 208000025499 G6PD deficiency Diseases 0.000 claims description 3
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 claims description 3
- 208000008605 glucosephosphate dehydrogenase deficiency Diseases 0.000 claims description 3
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 230000003698 anagen phase Effects 0.000 claims description 2
- DDENDDKMBDTHAX-UHFFFAOYSA-N 7-chloro-n-[[2-[(dimethylamino)methyl]cyclopenta-2,4-dien-1-yl]methyl]quinolin-4-amine;cyclopenta-1,3-diene;iron(2+) Chemical compound [Fe+2].C=1C=C[CH-]C=1.CN(C)CC1=CC=C[C-]1CNC1=CC=NC2=CC(Cl)=CC=C12 DDENDDKMBDTHAX-UHFFFAOYSA-N 0.000 description 20
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 15
- 229960003677 chloroquine Drugs 0.000 description 15
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 15
- 229950010451 ferroquine Drugs 0.000 description 15
- 241000223960 Plasmodium falciparum Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000013543 active substance Substances 0.000 description 6
- 239000003430 antimalarial agent Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 210000003936 merozoite Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241001505293 Plasmodium ovale Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229960001962 mefloquine Drugs 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical group N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 3
- 229960005179 primaquine Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 2
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000005469 Vivax Malaria Diseases 0.000 description 2
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical class C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- UCRHFBCYFMIWHC-UHFFFAOYSA-N piperaquine Chemical compound ClC1=CC=C2C(N3CCN(CC3)CCCN3CCN(CC3)C=3C4=CC=C(C=C4N=CC=3)Cl)=CC=NC2=C1 UCRHFBCYFMIWHC-UHFFFAOYSA-N 0.000 description 2
- 229950006717 piperaquine Drugs 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- WREVVZMUNPAPOV-UHFFFAOYSA-N 8-aminoquinoline Chemical group C1=CN=C2C(N)=CC=CC2=C1 WREVVZMUNPAPOV-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960004191 artemisinin Drugs 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical group [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000006204 intramuscular dosage form Substances 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000017259 schizogony Effects 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006203 subcutaneous dosage form Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
フェロキン 50mg
マンニトール 224mg
クロスカルメロースナトリウム 6mg
コーンスターチ 15mg
ヒドロキシプロピルメチルセルロース 2mg
ステアリン酸マグネシウム 3mg
以下の試験は、タイ国北西部(ターク県)においてShokloマラリア研究ユニット(SMRU)で診察を受けた、P.ビバックス(P.vivax)に感染してこの感染の急性期にある、同意が得られた患者から収集したP.ビバックス(P.vivax)の110例の単離体を対象に実施する。
用量/反応図を示している図2は、フェロキンおよびクロロキンについて得られたIC50(50%阻害濃度)の結果を例示している。
Claims (10)
- 先行請求項のいずれか一項に記載のフェロキンもしくはフェロキンのN−脱メチル化代謝産物またはこれらの医薬的に許容される塩の使用であって、プラスモディウム(Plasmodium)属の、生活環がヒト宿主における肝遅滞期を包含し、P.ビバックス(P.vivax)、P.オバール(P.ovale)およびP.マラリアエ(P.malariae)から選択される寄生虫によって誘発される感染症を治療および/または予防するための使用。
- 寄生虫は、P.ビバックス(P.vivax)であることを特徴とする、請求項1に記載の使用。
- 感染症は、血液細胞および肝細胞の感染症であることを特徴とする、請求項1および2のいずれかに記載の使用。
- 感染症は、血液細胞の感染症であることを特徴とする、請求項1から3のいずれか一項に記載の使用。
- 治療および/または予防は、未成熟トロホゾイト(「環状期」)および成熟トロホゾイトの寄生虫の成長期での血液細胞の感染症の治療および/または予防であることを特徴とする、請求項1から4のいずれか一項に記載の使用。
- 感染症は、肝細胞の感染症であることを特徴とする、請求項1から3のいずれか一項に記載の使用。
- 治療および予防は、ヒト肝細胞内に蓄積された静止ヒプノゾイト形の治療および予防であることを特徴とする、請求1から3および6のいずれか一項に記載の使用。
- 予防は、再発の予防に関することを特徴とする、請求項1から3、6および7のいずれか一項に記載の使用。
- 治療および/または予防は、良性三日熱の治療および/または予防であることを特徴とする、請求1から3、6および7のいずれか一項に記載の使用。
- 治療および/または予防は、グルコース−6−ホスフェートデヒドロゲナーゼ欠損症患者における感染症の治療および/または予防であることを特徴とする、請求1から3、6および7のいずれか一項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0905212 | 2009-10-30 | ||
FR0905212A FR2952823B1 (fr) | 2009-10-30 | 2009-10-30 | Utilisation de la ferroquine dans le traitement ou la prevention du paludisme |
PCT/FR2010/052331 WO2011051634A1 (fr) | 2009-10-30 | 2010-10-29 | Utilisation de la ferroquine dans le traitement ou la prevention du paludisme |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013509388A true JP2013509388A (ja) | 2013-03-14 |
JP2013509388A5 JP2013509388A5 (ja) | 2013-10-17 |
JP5820812B2 JP5820812B2 (ja) | 2015-11-24 |
Family
ID=42173412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012535910A Expired - Fee Related JP5820812B2 (ja) | 2009-10-30 | 2010-10-29 | マラリアの治療または予防におけるフェロキンの使用 |
Country Status (24)
Country | Link |
---|---|
US (1) | US20120270851A1 (ja) |
EP (1) | EP2493573B1 (ja) |
JP (1) | JP5820812B2 (ja) |
KR (1) | KR101701547B1 (ja) |
CN (1) | CN102655911A (ja) |
AP (1) | AP3019A (ja) |
AR (1) | AR078825A1 (ja) |
AU (1) | AU2010311223B2 (ja) |
BR (1) | BR112012010134A2 (ja) |
CA (1) | CA2779160C (ja) |
CL (1) | CL2012001125A1 (ja) |
CO (1) | CO6531490A2 (ja) |
EA (1) | EA023732B1 (ja) |
FR (1) | FR2952823B1 (ja) |
HK (1) | HK1173995A1 (ja) |
IL (1) | IL219444A (ja) |
JO (1) | JO2965B1 (ja) |
MA (1) | MA34273B1 (ja) |
MX (1) | MX2012005118A (ja) |
MY (1) | MY155833A (ja) |
NZ (1) | NZ599639A (ja) |
TW (1) | TW201130484A (ja) |
UY (1) | UY32986A (ja) |
WO (1) | WO2011051634A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102073961B1 (ko) | 2018-11-16 | 2020-02-05 | (주)프론트바이오 | 메트포르민 및 페로센계 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 약학적 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536900A (ja) * | 2005-04-20 | 2008-09-11 | サノフイ−アベンテイス | マラリア治療用のフェロキンとアーテミシニン誘導体との組合せ |
WO2009074649A1 (en) * | 2007-12-11 | 2009-06-18 | Universite Pierre Et Marie Curie-Paris Vi | Compounds for preventing and treating plasmodium infections |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2733985B1 (fr) | 1995-05-10 | 1997-07-18 | Univ Lille Sciences Tech | Complexes organometalliques du fer antipaludiques |
US7670631B2 (en) * | 2003-03-12 | 2010-03-02 | ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. | Method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists |
-
2009
- 2009-10-30 FR FR0905212A patent/FR2952823B1/fr active Active
-
2010
- 2010-10-27 JO JO2010375A patent/JO2965B1/en active
- 2010-10-29 MA MA34897A patent/MA34273B1/fr unknown
- 2010-10-29 JP JP2012535910A patent/JP5820812B2/ja not_active Expired - Fee Related
- 2010-10-29 AU AU2010311223A patent/AU2010311223B2/en not_active Ceased
- 2010-10-29 WO PCT/FR2010/052331 patent/WO2011051634A1/fr active Application Filing
- 2010-10-29 BR BR112012010134A patent/BR112012010134A2/pt not_active IP Right Cessation
- 2010-10-29 KR KR1020127010912A patent/KR101701547B1/ko active IP Right Grant
- 2010-10-29 MY MYPI2012001911A patent/MY155833A/en unknown
- 2010-10-29 AP AP2012006241A patent/AP3019A/xx active
- 2010-10-29 AR ARP100103991A patent/AR078825A1/es unknown
- 2010-10-29 EP EP10788113.8A patent/EP2493573B1/fr active Active
- 2010-10-29 NZ NZ599639A patent/NZ599639A/en not_active IP Right Cessation
- 2010-10-29 CA CA2779160A patent/CA2779160C/fr not_active Expired - Fee Related
- 2010-10-29 CN CN2010800490227A patent/CN102655911A/zh active Pending
- 2010-10-29 EA EA201290252A patent/EA023732B1/ru not_active IP Right Cessation
- 2010-10-29 MX MX2012005118A patent/MX2012005118A/es active IP Right Grant
- 2010-10-29 UY UY0001032986A patent/UY32986A/es not_active Application Discontinuation
- 2010-10-29 TW TW099137365A patent/TW201130484A/zh unknown
-
2012
- 2012-04-25 IL IL219444A patent/IL219444A/en not_active IP Right Cessation
- 2012-04-27 US US13/457,849 patent/US20120270851A1/en not_active Abandoned
- 2012-04-27 CL CL2012001125A patent/CL2012001125A1/es unknown
- 2012-04-27 CO CO12069256A patent/CO6531490A2/es not_active Application Discontinuation
-
2013
- 2013-02-01 HK HK13101425.8A patent/HK1173995A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008536900A (ja) * | 2005-04-20 | 2008-09-11 | サノフイ−アベンテイス | マラリア治療用のフェロキンとアーテミシニン誘導体との組合せ |
WO2009074649A1 (en) * | 2007-12-11 | 2009-06-18 | Universite Pierre Et Marie Curie-Paris Vi | Compounds for preventing and treating plasmodium infections |
Non-Patent Citations (3)
Title |
---|
JPN5013002672; 'ANNEX 10. TREATMENT OF P.VIVAX,P.OVALE AND P.MALARIAE INFECTIONS' GUIDELINES FOR THE TREATMENT OF MALARIA , 20060101, P225-239, WORLD HEALTH ORGANIZATION * |
JPN5013002673; BARENDS MARION: 'IN VITRO ACTIVITY OF FERROQUINE(SSR 97193)AGAINST PLASMODIUM FALCIPARUM ISOLATES 以下備考' MALARIA JOURNAL V6 N1, 20070627, BIOMED CENTRAL * |
JPN6014039719; Current Opinion in Microbiology 11, 2008, p.428-433 * |
Also Published As
Publication number | Publication date |
---|---|
BR112012010134A2 (pt) | 2016-06-07 |
KR20120100953A (ko) | 2012-09-12 |
WO2011051634A1 (fr) | 2011-05-05 |
FR2952823A1 (fr) | 2011-05-27 |
TW201130484A (en) | 2011-09-16 |
HK1173995A1 (en) | 2013-05-31 |
FR2952823B1 (fr) | 2012-04-20 |
JO2965B1 (en) | 2016-03-15 |
IL219444A (en) | 2016-02-29 |
KR101701547B1 (ko) | 2017-02-01 |
AU2010311223B2 (en) | 2015-10-29 |
JP5820812B2 (ja) | 2015-11-24 |
MA34273B1 (fr) | 2013-06-01 |
EA023732B1 (ru) | 2016-07-29 |
MY155833A (en) | 2015-12-15 |
CA2779160C (fr) | 2017-09-05 |
AR078825A1 (es) | 2011-12-07 |
NZ599639A (en) | 2014-08-29 |
US20120270851A1 (en) | 2012-10-25 |
CO6531490A2 (es) | 2012-09-28 |
CA2779160A1 (fr) | 2011-05-05 |
CN102655911A (zh) | 2012-09-05 |
AP3019A (en) | 2014-10-31 |
IL219444A0 (en) | 2012-06-28 |
AU2010311223A1 (en) | 2012-05-24 |
AP2012006241A0 (en) | 2012-04-30 |
CL2012001125A1 (es) | 2012-09-28 |
MX2012005118A (es) | 2012-07-23 |
EP2493573A1 (fr) | 2012-09-05 |
UY32986A (es) | 2011-05-31 |
EA201290252A1 (ru) | 2013-02-28 |
EP2493573B1 (fr) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Warrell et al. | Treatment and prevention of malaria | |
TWI387456B (zh) | 用於治療瘧疾之二茂鐵氯奎(ferroquine)及黃花蒿素(artemisinin)衍生物之組合 | |
US20110172268A1 (en) | Mechanism-based small-molecule parasite inhibitors | |
US20080227730A1 (en) | 9A-Carbamoyl and Thiocarbamoyl Azalides With Antimalarial Activity | |
WO2006075256A2 (en) | 9a-carbamoyl-ϝ-aminopropyl- and 9a-thiocarbamoyl-ϝ-aminopropyl-azalides with antimalarial activity | |
US6451813B1 (en) | Treatment of gastroparesis in certain patient groups | |
Shapiro et al. | Chemotherapy of protozoal infections | |
JP5820812B2 (ja) | マラリアの治療または予防におけるフェロキンの使用 | |
TW201000098A (en) | Combination of a bisthiazolium salt or a precursor thereof and artemisinin or a derivative thereof for the treatment of severe malaria | |
US20110124723A1 (en) | Compounds for Preventing and Treating Plasmodium Infections | |
US20220332685A1 (en) | Compound derived from quinoline, use of a compound, composition and method for the treatment or prophylaxis of a condition caused by a blood parasite | |
WO2017143964A1 (zh) | Quisinostat,一种新型的高效抗疟药物 | |
US20220265644A1 (en) | Fixed dose combination drug for the treatment of malaria | |
Roshan | A Review on the Importance of the Quinoline Ring in the Preparation of New Antimalarial Drugs | |
Luanting et al. | Research progress of antimalarial drugs | |
TW202327588A (zh) | 治療神經膠質母細胞瘤之方法 | |
AU2022210451A1 (en) | Compounds and methods for treating malaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130829 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130829 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140924 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150908 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151005 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5820812 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |